MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells-Reference-Cited by-同舟云学术

MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells

Published:2019-09-26 Issue:9 Volume:14 Page:e0223225
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ebert Karolin^ORCID,Mattes Julian,Kunzke Thomas,Zwingenberger Gwen,Luber Birgit

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference44 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;F Bray;CA Cancer J Clin,2018

2. Clinical impact of tumour biology in the management of gastroesophageal cancer;F Lordick;Nat Rev Clin Oncol,2016

3. New agents on the horizon in gastric cancer;F Lordick;Ann Oncol,2017

4. Targeted therapies for gastric cancer: failures and hopes from clinical trials;M Apicella;Oncotarget,2017

5. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines;S Keller;Mol Oncol,2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies;Cancers;2024-08-15

2. ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer;Epigenetics;2023-10-31

3. Knockdown of CALM2 increases the sensitivity to afatinib in HER2-amplified gastric cancer cells by regulating the Akt/FoxO3a/Puma axis;Toxicology in Vitro;2023-03

4. Signaling pathways and therapeutic interventions in gastric cancer;Signal Transduction and Targeted Therapy;2022-10-08

5. HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer;Molecular Imaging and Biology;2022-08-12